February 8, 2010 -
KineMed, Inc. a translational and personalized medicine development company, announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer’s disease and other neurodegenerative conditions. This agreement builds on the original collaboration between the two companies begun in June 2009.
“We are very pleased to be working with Bristol Myers Squibb to enable the development of their drugs intended to slow the progression of Alzheimer’s disease by novel mechanisms. KineMed is excited by the possibility that our novel measures of brain function could play a crucial role in advancing such potentially beneficial new medicines...
KineMed's Press Release -
